IFN-δ exerts opposing effects on T cell responsesdepending on the chronicity of the virus infection

Journal of Immunology

Volumn 192, Issue 8, 2014, Pages 3596-3606

  Misumi, Ichiro ^a   Whitmire, Jason K ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERFERON RECEPTOR;

ANIMAL; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; DISEASE MODEL; GENETICS; HUMORAL IMMUNITY; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; KNOCKOUT MOUSE; LYMPHOCYTIC CHORIOMENINGITIS; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; METABOLISM; MOUSE; NATURAL KILLER CELL; T LYMPHOCYTE SUBPOPULATION; VIRUS INFECTION;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DISEASE MODELS, ANIMAL; IMMUNITY, HUMORAL; IMMUNOLOGIC MEMORY; INTERFERON-GAMMA; KILLER CELLS, NATURAL; LYMPHOCYTIC CHORIOMENINGITIS; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; MICE; MICE, KNOCKOUT; RECEPTORS, INTERFERON; T-LYMPHOCYTE SUBSETS; VIRUS DISEASES;

EID: 84898619553     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1301705     Document Type: Article

References (118)

1. Kotenko, S. V. 2011. IFN-ls. Curr. Opin. Immunol. 23: 583-590.
2. Kotenko, S. V., G. Gallagher, V. V. Baurin, A. Lewis-Antes, M. Shen, N. K. Shah, J. A. Langer, F. Sheikh, H. Dickensheets, and R. P. Donnelly. 2003. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat. Immunol. 4: 69-77.
3. Sheppard, P., W. Kindsvogel, W. Xu, K. Henderson, S. Schlutsmeyer, T. E. Whitmore, R. Kuestner, U. Garrigues, C. Birks, J. Roraback, et al. 2003. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat. Immunol. 4: 63-68.
4. Lasfar, A., A. Lewis-Antes, S. V. Smirnov, S. Anantha, W. Abushahba, B. Tian, K. Reuhl, H. Dickensheets, F. Sheikh, R. P. Donnelly, et al. 2006. Characterization of the mouse IFN-lambda ligand-receptor system: IFN-lambdas exhibit antitumor activity against B16 melanoma. Cancer Res. 66: 4468-4477.
5. Karpala, A. J., K. R. Morris, M. M. Broadway, P. G. McWaters, T. E. O'Neil, K. E. Goossens, J. W. Lowenthal, and A. G. Bean. 2008. Molecular cloning, expression, and characterization of chicken IFN -lambda. J. Interferon Cytokine Res. 28: 341-350.
6. Qi, Z., P. Nie, C. J. Secombes, and J. Zou. 2010. Intron-containing type I and type III IFN coexist in amphibians: refuting the concept that a retroposition event gave rise to type I IFNs. J. Immunol. 184: 5038-5046.
7. Zhou, P., C. Cowled, S. Todd, G. Crameri, E. R. Virtue, G. A. Marsh, R. Klein, Z. Shi, L. F. Wang, and M. L. Baker. 2011. Type III IFNs in pteropid bats: differential expression patterns provide evidence for distinct roles in antiviral immunity. J. Immunol. 186: 3138-3147.
8. Manry, J., G. Laval, E. Patin, S. Fornarino, Y. Itan, M. Fumagalli, M. Sironi, M. Tichit, C. Bouchier, J. L. Casanova, et al. 2011. Evolutionary genetic dissection of human interferons. J. Exp. Med. 208: 2747-2759.
9. Pagliaccetti, N. E., and M. D. Robek. 2010. Interferon-l in HCV infection and therapy. Viruses 2: 1589-1602.
10. Ge, D., J. Fellay, A. J. Thompson, J. S. Simon, K. V. Shianna, T. J. Urban, E. L. Heinzen, P. Qiu, A. H. Bertelsen, A. J. Muir, et al. 2009. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461: 399-401.
11. Suppiah, V., M. Moldovan, G. Ahlenstiel, T. Berg, M. Weltman, M. L. Abate, M. Bassendine, U. Spengler, G. J. Dore, E. Powell, et al. 2009. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat. Genet. 41: 1100-1104.
12. Bibert, S., T. Roger, T. Calandra, M. Bochud, A. Cerny, N. Semmo, F. H. Duong, T. Gerlach, R. Malinverni, D. Moradpour, et al; Swiss Hepatitis C Cohort Study. 2013. IL28B expression depends on a novel TT/-G polymorphism which improves HCV clearance prediction. J. Exp. Med. 210: 1109-1116.
13. Antaki, N., S. Bibert, K. Kebbewar, F. Asaad, O. Baroudi, S. Alideeb, M. Hadad, D. Abboud, H. Sabah, P. Y. Bochud, and F. Negro. 2013. IL28B polymorphisms predict response to therapy among chronic hepatitis C patients with HCV genotype 4. J. Viral Hepat. 20: 59-64.
14. Ank, N., H. West, C. Bartholdy, K. Eriksson, A. R. Thomsen, and S. R. Paludan. 2006. Lambda interferon (IFN-lambda), a type III IFN, is induced by viruses and IFNs and displays potent antiviral activity against select virus infections in vivo. J. Virol. 80: 4501-4509.
15. Coccia, E. M., M. Severa, E. Giacomini, D. Monneron, M. E. Remoli, I. Julkunen, M. Cella, R. Lande, and G. Uzé. 2004. Viral infection and Toll-like receptor agonists induce a differential expression of type I and lambda interferons in human plasmacytoid and monocyte-derived dendritic cells. Eur. J. Immunol. 34: 796-805.
16. Okabayashi, T., T. Kojima, T. Masaki, S. Yokota, T. Imaizumi, H. Tsutsumi, T. Himi, N. Fujii, and N. Sawada. 2011. Type-III interferon, not type-I, is the predominant interferon induced by respiratory viruses in nasal epithelial cells. Virus Res. 160: 360-366.
17. Marukian, S., L. Andrus, T. P. Sheahan, C. T. Jones, E. D. Charles, A. Ploss, C. M. Rice, and L. B. Dustin. 2011. Hepatitis C virus induces interferon-l and interferon-stimulated genes in primary liver cultures. Hepatology 54: 1913-1923.
18. Megjugorac, N. J., G. E. Gallagher, and G. Gallagher. 2010. IL-4 enhances IFN-lambda1 (IL-29) production by plasmacytoid DCs via monocyte secretion of IL-1Ra. Blood 115: 4185-4190.
19. Wolk, K., K.Witte, E.Witte, S. Proesch, G. Schulze-Tanzil, K. Nasilowska, J. Thilo, K. Asadullah, W. Sterry, H. D. Volk, and R. Sabat. 2008. Maturing dendritic cells are an important source of IL-29 and IL-20 that may cooperatively increase the innate immunity of keratinocytes. J. Leukoc. Biol. 83: 1181-1193.
20. He, S. H., C. H. Song, Z. Liu, H. Zhang, W. Ma, L. F. Zhou, T. Mahmood, and P. C. Yang. 2012. Eosinophil-derived interferon-lambda contributes to initiation of allergen-related inflammation in the intestine. Cytokine 58: 186-192.
21. Zhang, X., T. W. Brann, M. Zhou, J. Yang, R. M. Oguariri, K. B. Lidie, H. Imamichi, D. W. Huang, R. A. Lempicki, M. W. Baseler, et al. 2011. Cutting edge: Ku70 is a novel cytosolic DNA sensor that induces type III rather than type I IFN. J. Immunol. 186: 4541-4545.
22. Bartlett, N. W., K. Buttigieg, S. V. Kotenko, and G. L. Smith. 2005. Murine interferon lambdas (type III interferons) exhibit potent antiviral activity in vivo in a poxvirus infection model. J. Gen. Virol. 86: 1589-1596.
23. Ank, N., and S. R. Paludan. 2009. Type III IFNs: new layers of complexity in innate antiviral immunity. Biofactors 35: 82-87.
24. Ank, N., M. B. Iversen, C. Bartholdy, P. Staeheli, R. Hartmann, U. B. Jensen, F. Dagnaes-Hansen, A. R. Thomsen, Z. Chen, H. Haugen, et al. 2008. An important role for type III interferon (IFN-lambda/IL-28) in TLR-induced antiviral activity. J. Immunol. 180: 2474-2485.
25. Yin, Z., J. Dai, J. Deng, F. Sheikh, M. Natalia, T. Shih, A. Lewis-Antes, S. B. Amrute, U. Garrigues, S. Doyle, et al. 2012. Type III IFNs are produced by and stimulate human plasmacytoid dendritic cells. J. Immunol. 189: 2735-2745.
26. Dumoutier, L., A. Tounsi, T. Michiels, C. Sommereyns, S. V. Kotenko, and J. C. Renauld. 2004. Role of the interleukin (IL)-28 receptor tyrosine residues for antiviral and antiproliferative activity of IL-29/interferon-lambda 1: similarities with type I interferon signaling. J. Biol. Chem. 279: 32269-32274.
27. Zhou, Z., O. J. Hamming, N. Ank, S. R. Paludan, A. L. Nielsen, and R. Hartmann. 2007. Type III interferon (IFN) induces a type I IFN-like response in a restricted subset of cells through signaling pathways involving both the Jak-STAT pathway and the mitogen-activated protein kinases. J. Virol. 81: 7749-7758.
28. Doyle, S. E., H. Schreckhise, K. Khuu-Duong, K. Henderson, R. Rosler, H. Storey, L. Yao, H. Liu, F. Barahmand-pour, P. Sivakumar, et al. 2006. Interleukin-29 uses a type 1 interferon-like program to promote antiviral responses in human hepatocytes. Hepatology 44: 896-906.
29. Maher, S. G., F. Sheikh, A. J. Scarzello, A. L. Romero-Weaver, D. P. Baker, R. P. Donnelly, and A. M. Gamero. 2008. IFNalpha and IFNlambda differ in their antiproliferative effects and duration of JAK/STAT signaling activity. Cancer Biol. Ther. 7: 1109-1115.
30. Ma, D., D. Jiang, M. Qing, J. M. Weidner, X. Qu, H. Guo, J. Chang, B. Gu, P. Y. Shi, T. M. Block, and J. T. Guo. 2009. Antiviral effect of interferon lambda against West Nile virus. Antiviral Res. 83: 53-60.
31. Pagliaccetti, N. E., R. Eduardo, S. H. Kleinstein, X. J. Mu, P. Bandi, and M. D. Robek. 2008. Interleukin-29 functions cooperatively with interferon to induce antiviral gene expression and inhibit hepatitis C virus replication. J. Biol. Chem. 283: 30079-30089.
32. Perez-Martin, E., M. Weiss, F. Diaz-San Segundo, J. M. Pacheco, J. Arzt, M. J. Grubman, and T. de los Santos. 2012. Bovine type III interferon significantly delays and reduces the severity of foot-and-mouth disease in cattle. J. Virol. 86: 4477-4487.
33. Li, J., L. Ye, X. Wang, S. Hu, and W. Ho. 2012. Induction of interferon-g contributes to Toll-like receptor 3-mediated herpes simplex virus type 1 inhibition in astrocytes. J. Neurosci. Res. 90: 399-406.
34. Zhou, L., J. Li, X. Wang, L. Ye, W. Hou, J. Ho, H. Li, and W. Ho. 2011. IL-29/ IL-28A suppress HSV-1 infection of human NT2-N neurons. J. Neurovirol. 17: 212-219.
35. Li, J., S. Hu, L. Zhou, L. Ye, X. Wang, J. Ho, and W. Ho. 2011. Interferon lambda inhibits herpes simplex virus type I infection of human astrocytes and neurons. Glia 59: 58-67.
36. Mordstein, M., E. Neugebauer, V. Ditt, B. Jessen, T. Rieger, V. Falcone, F. Sorgeloos, S. Ehl, D. Mayer, G. Kochs, et al. 2010. Lambda interferon renders epithelial cells of the respiratory and gastrointestinal tracts resistant to viral infections. J. Virol. 84: 5670-5677.
37. Mordstein, M., G. Kochs, L. Dumoutier, J. C. Renauld, S. R. Paludan, K. Klucher, and P. Staeheli. 2008. Interferon-lambda contributes to innate immunity of mice against influenza Avirus but not against hepatotropic viruses. PLoS Pathog. 4: e1000151.
38. Svetlikova, D., P. Kabat, A. Ohradanova, J. Pastorek, and T. Betakova. 2010. Influenza A virus replication is inhibited in IFN-l2 and IFN-l3 transfected or stimulated cells. Antiviral Res. 88: 329-333.
39. Hou, W., X. Wang, L. Ye, L. Zhou, Z. Q. Yang, E. Riedel, and W. Z. Ho. 2009. Lambda interferon inhibits human immunodeficiency virus type 1 infection of macrophages. J. Virol. 83: 3834-3842.
40. Pagliaccetti, N. E., E. N. Chu, C. R. Bolen, S. H. Kleinstein, and M. D. Robek. 2010. Lambda and alpha interferons inhibit hepatitis B virus replication through a common molecular mechanism but with different in vivo activities. Virology 401: 197-206.
41. Zhu, H., M. Butera, D. R. Nelson, and C. Liu. 2005. Novel type I interferon IL-28A suppresses hepatitis C viral RNA replication. Virol. J. 2: 80.
42. Robek, M. D., B. S. Boyd, and F. V. Chisari. 2005. Lambda interferon inhibits hepatitis B and C virus replication. J. Virol. 79: 3851-3854.
43. Hong, S. H., O. Cho, K. Kim, H. J. Shin, S. V. Kotenko, and S. Park. 2007. Effect of interferon-lambda on replication of hepatitis B virus in human hepatoma cells. Virus Res. 126: 245-249.
44. Heinze, B., S. Frey, M. Mordstein, A. Schmitt-Gräff, S. Ehl, U. J. Buchholz, P. L. Collins, P. Staeheli, and C. D. Krempl. 2011. Both nonstructural proteins NS1 and NS2 of pneumonia virus of mice are inhibitors of the interferon type I and type III responses in vivo. J. Virol. 85: 4071-4084.
45. Ding, Q., B. Huang, J. Lu, Y. J. Liu, and J. Zhong. 2012. Hepatitis C virus NS3/ 4A protease blocks IL-28 production. Eur. J. Immunol. 42: 2374-2382.
46. Huang, J., S. V. Smirnov, A. Lewis-Antes,M. Balan, W. Li, S. Tang, G. V. Silke, M. M. Putz, G. L. Smith, and S. V. Kotenko. 2007. Inhibition of type I and type III interferons by a secreted glycoprotein from Yaba-like disease virus. Proc. Natl. Acad. Sci. USA 104: 9822-9827.
47. Bandi, P., N. E. Pagliaccetti, and M. D. Robek. 2010. Inhibition of type III interferon activity by orthopoxvirus immunomodulatory proteins. J. Interferon Cytokine Res. 30: 123-134.
48. Muir, A. J., M. L. Shiffman, A. Zaman, B. Yoffe, A. de la Torre, S. Flamm, S. C. Gordon, P. Marotta, J. M. Vierling, J. C. Lopez-Talavera, et al. 2010. Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection. Hepatology 52: 822-832.
49. Sommereyns, C., S. Paul, P. Staeheli, and T. Michiels. 2008. IFN-lambda (IFNlambda) is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo. PLoS Pathog. 4: e1000017.
50. Pott, J., T. Mahlakö iv, M. Mordstein, C. U. Duerr, T. Michiels, S. Stockinger, P. Staeheli, and M. W. Hornef. 2011. IFN-lambda determines the intestinal epithelial antiviral host defense. Proc. Natl. Acad. Sci. USA 108: 7944-7949.
51. Witte, K., G. Gruetz, H. D. Volk, A. C. Looman, K. Asadullah, W. Sterry, R. Sabat, and K. Wolk. 2009. Despite IFN-lambda receptor expression, blood immune cells, but not keratinocytes or melanocytes, have an impaired response to type III interferons: implications for therapeutic applications of these cytokines. Genes Immun. 10: 702-714.
52. Jordan, W. J., J. Eskdale, M. Boniotto, M. Rodia, D. Kellner, and G. Gallagher. 2007. Modulation of the human cytokine response by interferon lambda-1 (IFN-lambda1/IL-29). Genes Immun. 8: 13-20.
53. Morrow, M. P., J. Yan, P. Pankhong, D. J. Shedlock, M. G. Lewis, K. Talbott, R. Toporovski, A. S. Khan, N. Y. Sardesai, and D. B. Weiner. 2010. IL-28B/ IFN-lambda 3 drives granzyme B loading and significantly increases CTL killing activity in macaques. Mol. Ther. 18: 1714-1723.
54. Morrow, M. P., J. Yan, P. Pankhong, B. Ferraro, M. G. Lewis, A. S. Khan, N. Y. Sardesai, and D. B. Weiner. 2010. Unique Th1/Th2 phenotypes induced during priming and memory phases by use of interleukin-12 (IL-12) or IL-28B vaccine adjuvants in rhesus macaques. Clin. Vaccine Immunol. 17: 1493-1499.
55. Mennechet, F. J., and G. Uzé. 2006. Interferon-lambda-treated dendritic cells specifically induce proliferation of FOXP3-expressing suppressor T cells. Blood 107: 4417-4423.
56. Morrow, M. P., P. Pankhong, D. J. Laddy, K. A. Schoenly, J. Yan, N. Cisper, and D. B. Weiner. 2009. Comparative ability of IL-12 and IL-28B to regulate Treg populations and enhance adaptive cellular immunity. Blood 113: 5868-5877.
57. Jordan, W. J., J. Eskdale, S. Srinivas, V. Pekarek, D. Kelner, M. Rodia, and G. Gallagher. 2007. Human interferon lambda-1 (IFN-lambda1/IL-29) modulates the Th1/Th2 response. Genes Immun. 8: 254-261.
58. Koltsida, O., M. Hausding, A. Stavropoulos, S. Koch, G. Tzelepis, C. Ubel, S. V. Kotenko, P. Sideras, H. A. Lehr, M. Tepe, et al. 2011. IL-28A (IFN-l2) modulates lung DC function to promote Th1 immune skewing and suppress allergic airway disease. EMBO Mol. Med. 3: 348-361.
59. Chi, B., H. L. Dickensheets, K. M. Spann, M. A. Alston, C. Luongo, L. Dumoutier, J. Huang, J. C. Renauld, S. V. Kotenko, M. Roederer, et al. 2006. Alpha and lambda interferon together mediate suppression of CD4 T cells induced by respiratory syncytial virus. J. Virol. 80: 5032-5040.
60. Ahmed, R., A. Salmi, L. D. Butler, J. M. Chiller, and M. B. Oldstone. 1984. Selection of genetic variants of lymphocytic choriomeningitis virus in spleens of persistently infected mice. Role in suppression of cytotoxic T lymphocyte response and viral persistence. J. Exp. Med. 160: 521-540.
61. Foulds, K. E., L. A. Zenewicz, D. J. Shedlock, J. Jiang, A. E. Troy, and H. Shen. 2002. Cutting edge: CD4 and CD8 T cells are intrinsically different in their proliferative responses. J. Immunol. 168: 1528-1532.
62. Wang, N., R. A. Strugnell, O. L. Wijburg, and T. C. Brodnicki. 2013. Systemic infection of Mice with Listeria monocytogenes to characterize host immune responses. Methods Mol. Biol. 1031: 125-144.
63. Ike, F., F. Bourgade, K. Ohsawa, H. Sato, S. Morikawa, M. Saijo, I. Kurane, K. Takimoto, Y. K. Yamada, J. Jaubert, et al. 2007. Lymphocytic choriomeningitis infection undetected by dirty-bedding sentinel monitoring and revealed after embryo transfer of an inbred strain derived from wild mice. Comp. Med. 57: 272-281.
64. Whitmire, J. K., J. T. Tan, and J. L. Whitton. 2005. Interferon-gamma acts directly on CD8+ T cells to increase their abundance during virus infection. J. Exp. Med. 201: 1053-1059.
65. Foster, B., C. Prussin, F. Liu, J. K. Whitmire, and J. L. Whitton. 2007. Detection of intracellular cytokines by flow cytometry. Curr. Protoc. Immunol. 78: 6.24.1-6.24.21.
66. Mothé, B. R., B. S. Stewart, C. Oseroff, H. H. Bui, S. Stogiera, Z. Garcia, C. Dow, M. P. Rodriguez-Carreno, M. Kotturi, V. Pasquetto, et al. 2007. Chronic lymphocytic choriomeningitis virus infection actively down-regulates CD4+ T cell responses directed against a broad range of epitopes. J. Immunol. 179: 1058-1067.
67. Blanchard-Rohner, G., G. Galli, E. A. Clutterbuck, and A. J. Pollard. 2010. Comparison of a limiting dilution assay and ELISpot for detection of memory B-cells before and after immunisation with a protein-polysaccharide conjugate vaccine in children. J. Immunol. Methods 358: 46-55.
68. Crotty, S., R. D. Aubert, J. Glidewell, and R. Ahmed. 2004. Tracking human antigen-specific memory B cells: a sensitive and generalized ELISPOT system. J. Immunol. Methods 286: 111-122.
69. Whitmire, J. K., M. K. Slifka, I. S. Grewal, R. A. Flavell, and R. Ahmed. 1996. CD40 ligand-deficient mice generate a normal primary cytotoxic T-lymphocyte response but a defective humoral response to a viral infection. J. Virol. 70: 8375-8381.
70. Wang, Y., M. Swiecki, M. Cella, G. Alber, R. D. Schreiber, S. Gilfillan, and M. Colonna. 2012. Timing and magnitude of type I interferon responses by distinct sensors impact CD8 T cell exhaustion and chronic viral infection. Cell Host Microbe 11: 631-642.
71. Sato, A., M. Ohtsuki, M. Hata, E. Kobayashi, and T. Murakami. 2006. Antitumor activity of IFN-lambda in murine tumor models. J. Immunol. 176: 7686-7694.
72. Jewell, N. A., T. Cline, S. E. Mertz, S. V. Smirnov, E. Flanö, C. Schindler, J. L. Grieves, R. K. Durbin, S. V. Kotenko, and J. E. Durbin. 2010. Lambda interferon is the predominant interferon induced by influenza A virus infection in vivo. J. Virol. 84: 11515-11522.
73. Khaitov, M. R., V. Laza-Stanca, M. R. Edwards, R. P. Walton, G. Rohde, M. Contoli, A. Papi, L. A. Stanciu, S. V. Kotenko, and S. L. Johnston. 2009. Respiratory virus induction of alpha-, beta-and lambda-interferons in bronchial epithelial cells and peripheral blood mononuclear cells. Allergy 64: 375-386.
74. Whitmire, J. K., N. Benning, and J. L. Whitton. 2005. Cutting edge: early IFNgamma signaling directly enhances primary antiviral CD4+ T cell responses. J. Immunol. 175: 5624-5628.
75. Whitmire, J. K., B. Eam, N. Benning, and J. L. Whitton. 2007. Direct interferon-gamma signaling dramatically enhances CD4+ and CD8+ T cell memory. J. Immunol. 179: 1190-1197.
76. Kolumam, G. A., S. Thomas, L. J. Thompson, J. Sprent, and K. Murali-Krishna. 2005. Type I interferons act directly on CD8 T cells to allow clonal expansion and memory formation in response to viral infection. J. Exp. Med. 202: 637-650.
77. Havenar-Daughton, C., G. A. Kolumam, and K. Murali-Krishna. 2006. Cutting edge: the direct action of type I IFN on CD4 T cells is critical for sustaining clonal expansion in response to a viral but not a bacterial infection. J. Immunol. 176: 3315-3319.
78. Masopust, D., K. Murali-Krishna, and R. Ahmed. 2007. Quantitating the magnitude of the lymphocytic choriomeningitis virus-specific CD8 T-cell response: it is even bigger than we thought. J. Virol. 81: 2002-2011.
79. Rai, D., N. L. Pham, J. T. Harty, and V. P. Badovinac. 2009. Tracking the total CD8 T cell response to infection reveals substantial discordance in magnitude and kinetics between inbred and outbred hosts. J. Immunol. 183: 7672-7681.
80. Murali-Krishna, K., J. D. Altman, M. Suresh, D. J. Sourdive, A. J. Zajac, J. D. Miller, J. Slansky, and R. Ahmed. 1998. Counting antigen-specific CD8 T cells: a reevaluation of bystander activation during viral infection. Immunity 8: 177-187.
81. Srinivas, S., J. Dai, J. Eskdale, G. E. Gallagher, N. J. Megjugorac, and G. Gallagher. 2008. Interferon-lambda1 (interleukin-29) preferentially downregulates interleukin-13 over other T helper type 2 cytokine responses in vitro. Immunology 125: 492-502.
82. Dai, J., N. J. Megjugorac, G. E. Gallagher, R. Y. Yu, and G. Gallagher. 2009. IFN-lambda1 (IL-29) inhibits GATA3 expression and suppresses Th2 responses in human naive and memory T cells. Blood 113: 5829-5838.
83. Crotty, S., E. N. Kersh, J. Cannons, P. L. Schwartzberg, and R. Ahmed. 2003. SAP is required for generating long-term humoral immunity. Nature 421: 282-287.
84. Joshi, N. S., W. Cui, A. Chandele, H. K. Lee, D. R. Urso, J. Hagman, L. Gapin, and S. M. Kaech. 2007. Inflammation directs memory precursor and short-lived effector CD8(+) T cell fates via the graded expression of T-bet transcription factor. Immunity 27: 281-295.
85. Dooms, H., K. Wolslegel, P. Lin, and A. K. Abbas. 2007. Interleukin-2 enhances CD4+ T cell memory by promoting the generation of IL-7R alphaexpressing cells. J. Exp. Med. 204: 547-557.
86. Williams, M. A., A. J. Tyznik, and M. J. Bevan. 2006. Interleukin-2 signals during priming are required for secondary expansion of CD8+ memory T cells. Nature 441: 890-893.
87. D'Souza, W. N., and L. Lefrançois. 2003. IL-2 is not required for the initiation of CD8 T cell cycling but sustains expansion. J. Immunol. 171: 5727-5735.
88. Blattman, J. N., J. M. Grayson, E. J. Wherry, S. M. Kaech, K. A. Smith, and R. Ahmed. 2003. Therapeutic use of IL-2 to enhance antiviral T-cell responses in vivo. Nat. Med. 9: 540-547.
89. Kristensen, N. N., J. P. Christensen, and A. R. Thomsen. 2002. High numbers of IL-2-producing CD8+ T cells during viral infection: correlation with stable memory development. J. Gen. Virol. 83: 2123-2133.
90. Ramos, E. L. 2010. Preclinical and clinical development of pegylated interferon-lambda 1 in chronic hepatitis C. J. Interferon Cytokine Res. 30: 591-595.
91. Waggoner, S. N., M. Cornberg, L. K. Selin, and R. M. Welsh. 2012. Natural killer cells act as rheostats modulating antiviral T cells. Nature 481: 394-398.
92. Waggoner, S. N., R. T. Taniguchi, P. A. Mathew, V. Kumar, and R. M. Welsh. 2010. Absence of mouse 2B4 promotes NK cell-mediated killing of activated CD8+ T cells, leading to prolonged viral persistence and altered pathogenesis. J. Clin. Invest. 120: 1925-1938.
93. Lang, P. A., K. S. Lang, H. C. Xu, M. Grusdat, I. A. Parish, M. Recher, A. R. Elford, S. Dhanji, N. Shaabani, C. W. Tran, et al. 2012. Natural killer cell activation enhances immune pathology and promotes chronic infection by limiting CD8+ T-cell immunity. Proc. Natl. Acad. Sci. USA 109: 1210-1215.
94. Cook, K. D., and J. K. Whitmire. 2013. The depletion of NK cells prevents T cell exhaustion to efficiently control disseminating virus infection. J. Immunol. 190: 641-649.
95. Baize, S., D. Pannetier, C. Faure, P. Marianneau, I. Marendat, M. C. Georges-Courbot, and V. Deubel. 2006. Role of interferons in the control of Lassa virus replication in human dendritic cells and macrophages. Microbes Infect. 8: 1194-1202.
96. Megjugorac, N. J., G. E. Gallagher, and G. Gallagher. 2009. Modulation of human plasmacytoid DC function by IFN-lambda1 (IL-29). J. Leukoc. Biol. 86: 1359-1363.
97. Dolganiuc, A., K. Kodys, C. Marshall, B. Saha, S. Zhang, S. Bala, and G. Szabo. 2012. Type III interferons, IL-28 and IL-29, are increased in chronic HCV infection and induce myeloid dendritic cell-mediated FoxP3+ regulatory T cells. PLoS ONE 7: e44915.
98. Rynda, A., M. Maddaloni, J. Ochoa-Repa'raz, G. Callis, and D. W. Pascual. 2010. IL-28 supplants requirement for T(reg) cells in protein sigma1-mediated protection against murine experimental autoimmune encephalomyelitis (EAE). PLoS ONE 5: e8720.
99. Brand, S., F. Beigel, T. Olszak, K. Zitzmann, S. T. Eichhorst, J. M. Otte, J. Diebold, H. Diepolder, B. Adler, C. J. Auernhammer, et al. 2005. IL-28A and IL-29 mediate antiproliferative and antiviral signals in intestinal epithelial cells and murine CMV infection increases colonic IL-28A expression. Am. J. Physiol. Gastrointest. Liver Physiol. 289: G960-G968.
100. Siebler, J., S. Wirtz, B. Weigmann, I. Atreya, E. Schmitt, A. Kreft, P. R. Galle, and M. F. Neurath. 2007. IL-28A is a key regulator of T-cell-mediated liver injury via the T-box transcription factor T-bet. Gastroenterology 132: 358-371.
101. He, S. H., X. Chen, C. H. Song, Z. Q. Liu, L. F. Zhou, W. J. Ma, L. D. Zhao, T. L. Li, S. G. Tang, Z. Xing, and P. C. Yang. 2011. Interferon-lambda mediates oral tolerance and inhibits antigen-specific, T-helper 2 cell-mediated inflammation in mouse intestine. Gastroenterology 141: 249-258, 258.1-2.
102. Dickensheets, H., F. Sheikh, O. Park, B. Gao, and R. P. Donnelly. 2013. Interferon-lambda (IFN-l) induces signal transduction and gene expression in human hepatocytes, but not in lymphocytes or monocytes. J. Leukoc. Biol. 93: 377-385.
103. Cui, W., Y. Liu, J. S. Weinstein, J. Craft, and S. M. Kaech. 2011. An interleukin-21-interleukin-10-STAT3 pathway is critical for functional maturation of memory CD8+ T cells. Immunity 35: 792-805.
104. Brooks, D. G., K. B. Walsh, H. Elsaesser, and M. B. Oldstone. 2010. IL-10 directly suppresses CD4 but not CD8 T cell effector and memory responses following acute viral infection. Proc. Natl. Acad. Sci. USA 107: 3018-3023.
105. Brooks, D. G., S. J. Ha, H. Elsaesser, A. H. Sharpe, G. J. Freeman, and M. B. Oldstone. 2008. IL-10 and PD-L1 operate through distinct pathways to suppress T-cell activity during persistent viral infection. Proc. Natl. Acad. Sci. USA 105: 20428-20433.
106. Biswas, P. S., V. Pedicord, A. Ploss, E. Menet, I. Leiner, and E. G. Pamer. 2007. Pathogen-specific CD8 T cell responses are directly inhibited by IL-10. J. Immunol. 179: 4520-4528.
107. Brooks, D. G., M. J. Trifilo, K. H. Edelmann, L. Teyton, D. B. McGavern, and M. B. Oldstone. 2006. Interleukin-10 determines viral clearance or persistence in vivo. Nat. Med. 12: 1301-1309.
108. Ejrnaes, M., C. M. Filippi, M. M. Martinic, E. M. Ling, L. M. Togher, S. Crotty, and M. G. von Herrath. 2006. Resolution of a chronic viral infection after interleukin-10 receptor blockade. J. Exp. Med. 203: 2461-2472.
109. Brooks, D. G., A. M. Lee, H. Elsaesser, D. B. McGavern, and M. B. Oldstone. 2008. IL-10 blockade facilitates DNA vaccine-induced T cell responses and enhances clearance of persistent virus infection. J. Exp. Med. 205: 533-541.
110. Hahm, B., M. J. Trifilo, E. I. Zuniga, and M. B. Oldstone. 2005. Viruses evade the immune system through type I interferon-mediated STAT2-dependent, but STAT1-independent, signaling. Immunity 22: 247-257.
111. Wilson, E. B., D. H. Yamada, H. Elsaesser, J. Herskovitz, J. Deng, G. Cheng, B. J. Aronow, C. L. Karp, and D. G. Brooks. 2013. Blockade of chronic type I interferon signaling to control persistent LCMV infection. Science 340: 202-207.
112. Teijaro, J. R., C. Ng, A. M. Lee, B. M. Sullivan, K. C. Sheehan, M. Welch, R. D. Schreiber, J. C. de la Torre, and M. B. Oldstone. 2013. Persistent LCMV infection is controlled by blockade of type I interferon signaling. Science 340: 207-211.
113. Kamphuis, E., T. Junt, Z. Waibler, R. Forster, and U. Kalinke. 2006. Type I interferons directly regulate lymphocyte recirculation and cause transient blood lymphopenia. Blood 108: 3253-3261.
114. Schattner, A., A. Meshorer, and D. Wallach. 1983. Involvement of interferon in virus-induced lymphopenia. Cell. Immunol. 79: 11-25.
115. Ng, C. T., B. P. Nayak, C. Schmedt, and M. B. Oldstone. 2012. Immortalized clones of fibroblastic reticular cells activate virus-specific T cells during virus infection. Proc. Natl. Acad. Sci. USA 109: 7823-7828.
116. Mueller, S. N., M. Matloubian, D. M. Clemens, A. H. Sharpe, G. J. Freeman, S. Gangappa, C. P. Larsen, and R. Ahmed. 2007. Viral targeting of fibroblastic reticular cells contributes to immunosuppression and persistence during chronic infection. Proc. Natl. Acad. Sci. USA 104: 15430-15435.
117. Sevilla, N., D. B. McGavern, C. Teng, S. Kunz, and M. B. Oldstone. 2004. Viral targeting of hematopoietic progenitors and inhibition of DC maturation as a dual strategy for immune subversion. J. Clin. Invest. 113: 737-745.
118. Sevilla, N., S. Kunz, A. Holz, H. Lewicki, D. Homann, H. Yamada, K. P. Campbell, J. C. de La Torre, and M. B. Oldstone. 2000. Immunosuppression and resultant viral persistence by specific viral targeting of dendritic cells. J. Exp. Med. 192: 1249-1260.